JAZZ news

Jazz Pharmaceuticals amended its senior secured credit agreement by Amendment No. 4, effective September 23, 2026. This corporate action maintains financial flexibility and credit terms for the company through 2029.

Jazz Pharmaceuticals completed the acquisition of Actio Biosciences for $820 million upfront to add ABS-1230. This precise, oral small-molecule aims to treat all KCNT1-related epilepsy patients, enhancing Jazz's rare disease portfolio.

Jazz Pharmaceuticals announced a definitive agreement to acquire Actio Biosciences for $820 million upfront to acquire ABS-1230, a potential precision therapy for KCNT1+ epilepsy, which currently has no FDA-approved treatments.

Jazz Pharmaceuticals and AbCellera announced a collaboration to discover next-generation T-cell engaging multispeci​fic antibodies, with Jazz paying $56 million upfront and eligible for up to $792 million in milestone payments per program. The partnership expands Jazz's oncology focus on gastrointes…